Peter Cancelmo Sells 25,000 Shares of Omeros (NASDAQ:OMER) Stock

Omeros Corporation (NASDAQ:OMER) VP Peter Cancelmo sold 25,000 shares of the company’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of $18.65, for a total value of $466,250.00. Following the sale, the vice president owned 200 shares of the company’s stock, valued at $3,730. The trade was a 99.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Omeros Stock Performance

Omeros stock opened at $18.86 on Thursday. Omeros Corporation has a 52 week low of $3.94 and a 52 week high of $19.65. The stock has a market capitalization of $1.37 billion, a P/E ratio of 14.73 and a beta of 2.60. The stock has a fifty day moving average of $13.14 and a 200-day moving average of $12.19.

Omeros (NASDAQ:OMER) last issued its earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.29. The firm had revenue of $28.53 million during the quarter, compared to analyst estimates of $12.69 million. On average, research analysts forecast that Omeros Corporation will post -0.37 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on OMER. HC Wainwright restated a “buy” rating on shares of Omeros in a research report on Monday, July 27th. Wall Street Zen raised shares of Omeros from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. Zacks Research lowered Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Finally, Weiss Ratings upgraded Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $38.00.

Institutional Investors Weigh In On Omeros

A number of large investors have recently bought and sold shares of OMER. State of Wyoming bought a new position in shares of Omeros during the 4th quarter worth about $25,000. B. Riley Wealth Advisors Inc. bought a new stake in Omeros in the 2nd quarter valued at about $32,000. Caitong International Asset Management Co. Ltd acquired a new position in Omeros during the 4th quarter worth approximately $33,000. Assetmark Inc. acquired a new position in Omeros during the 1st quarter worth approximately $38,000. Finally, Tower Research Capital LLC TRC boosted its holdings in Omeros by 829.6% in the second quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 11,971 shares in the last quarter. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.